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Plasmodium falciparum infections of the placenta remain a major medical challenge among
pregnant women in sub-Saharan Africa. A number of factors influence the prevalence of
placental malaria in pregnant women, including maternal age, gravidity, use of prophylaxis,
nutrition, host genetics, and level of anti-parasite immunity, as well as parasite genetics and
transmission rates [1]. Maternal anemia has been shown to be one of the major complica-
tions of placental malaria in sub-SaharanAfrica. The mechanisms by which malaria causes
anemia are fairly well understood. The pathophysiology of malaria-associated anemia is
multifactorial. The most likely mechanisms include (i) hemolysis or the direct destruction of
parasitized red blood cells that occurs both intravascularly and by sequestration in the mi-
crocirculation, mainly in the spleen; (ii) specific/nonspecific immune responses, whereby
red cell survival is shortened; (iii) nonspecific, defective, red cell production, which depresses
erythropoiesis, inhibits reticulocyte release, and prematurely destructs red cells during mat-
uration in the bone marrow; and (iv) hypersplenism associated with a reduction in all three
blood cell series, that is, causing not only anemia but also thrombocytopenia and leucopenia
[2,3].
The relationship between maternal anemia with obstetric factors, however, is not fully un-
derstood, and, thus, evaluating the link between malaria, obstetric disorders, and maternal
death has been recommended [4]. There have been efforts to quantify the contribution of
malaria to maternal morbidity and mortality with the expectation that this would provide the
evidence necessary to improve the effectiveness of advocacy to incorporate malaria preven-
tion strategies in Safe Motherhood Programs [5,6]. The effects of placental malaria on ma-
ternal health can better be understood when considered in relation with various maternal
parameters, including maternal age, parity, peripheral malaria infection, anemia, and HIV in-
fection.
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Increased Morbidity and Mortality
Although pregnant women in malaria
endemic areas have higher rates of para-
sitemia and parasite density compared with
non-pregnant women, infection is largely
asymptomatic because some degree of pre-
existing immunity is retained during preg-
nancy [7]. However, even malaria-immune
women (i.e., those who have evolved some
level of immunity against severe infection
as a result of long residence in areas of sta-
ble malaria transmission) are susceptible to
placental malaria [1,8,9]. Because so many
parasites become sequestered within the pla-
centa, peripheral blood smears often fail to
detect evidence of infection. The resulting
lack of appropriate or timely treatment may
lead to adverse pregnancy outcome, includ-
ing severe anemia, which is the main mater-
nal consequence of malaria and can be
deadly [7].Apart from anemia, malaria may
contribute to maternal mortality by increas-
ing the risk and severity of obstetric condi-
tions such as pre-eclampsia/eclampsia and
postpartum hemorrhage by as much as 50
percent [10,11].
Maternal anemia
Anemia is the most common conse-
quence of P. falciparum malaria infection.
In sub-Saharan Africa, it is estimated that
between 200,000 and 500,000 pregnant
women develop severe anemia as a result of
malaria [12], and P. falciparum malaria in
pregnancy is the primary cause of up to
10,000 maternal anemia-related deaths in
sub-Saharan Africa annually [6,13]. How-
ever, there have been conflicting reports
from parts of sub-Saharan Africa on the re-
lationship between placental malaria and
maternal anemia.An earlier report from the
Ubangi district of Zaire noted that malarious
placentas had no consistent relationship to
maternal anemia [14]. In other studies, ma-
ternal anemia and placental malaria were as-
sociated in all gravidity and age groups, with
maternal anemia higher among women with
placental malaria than those without placen-
tal malaria (by gravidity, prevalence ranged
from 28.8 percent to 31.6 percent for posi-
tive cases and 15.3 percent to 16.7 percent
for negative cases; by age, prevalence
ranged from 26.5 percent to 31.8 percent for
positive cases and 15.3 percent to 17.7 per-
cent for negative cases) [1]. The reason for
this variation is not clear, but it may be con-
nected to the complex and multifactorial eti-
ology of anemia in pregnancy in
sub-SaharanAfrica [2].
In most areas of malaria endemicity,
many other causes of anemia have been
identified, including both nutritional (iron,
folate, and protein deficiency) and non-nu-
tritional (hookworm or HIV infection, he-
moglobinopathy) factors [3,15]. Since many
of these causes of anemia occur concurrently
in pregnancy and no unique hallmarks of
malaria-driven anemia have been identified,
it is difficult to evaluate the contribution
made to anemia in pregnancy by placental
malaria infection [16].Apart from its signif-
icant contribution to maternal mortality and
to both maternal and fetal morbidity, anemia
in pregnancy is a risk factor for infant iron
deficiency anemia [17] that, if left uncor-
rected, can be associated with adverse be-
havioral and cognitive development [18].
Severe anemia in pregnancy is an important
direct and indirect cause of maternal death.
During pregnancy, severe anemia may result
in circulatory changes associated with an in-
creased risk of heart failure and acute onset
of anemia due to rapid cardiac decompensa-
tion and decreases in hemoglobin (Hb) con-
centration to < 80g/L. Such changes can
result in the failure of compensatory mech-
anisms, accumulation of lactic acid, and
breathlessness at rest [19]. Furthermore, dur-
ing labor, women with severe anemia are
less able to endure even moderate blood loss
and, as a consequence, are at a higher risk of
requiring a blood transfusion during delivery
[3]. For the fetus, severe maternal anemia
may result in intrauterine growth retarda-
tion, still birth, and low birth weight [20-23].
The mechanism of malaria-driven anemia
can be described in association with iron sta-
tus in pregnancy. The iron status in preg-
nancy is affected by malaria parasites, which
influences the anemia observed in preg-
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through (i) reducing intestinal iron absorp-
tion; (ii) sequestrating iron within the malar-
ial pigment hemozoin; (iii) consuming iron
for its own metabolism; (iv)
promoting/stimulating the mobilization of
iron to body stores; and (v) releasing iron
into the circulation during intravascular he-
molysis [2,3].
Maternal Age and Malaria Infection
A number of studies conducted in sub-
Saharan Africa have reported a significant
association between maternal age and
malaria infection during pregnancy [24-27].
In a study conducted in Blantyre, Malawi,
after stratifying by gravidity, associations
between age and parasite prevalence were
stronger than those between gravidity and
prevalence after stratifying by age [25].
Under conditions of low-to-moderate trans-
mission, pregnancy-specific immunity is
slow to develop, and age-related immunity
may influence malaria prevalence in child-
bearing years [25].
Studies have shown that young women
of child-bearing age may be more suscepti-
ble than older women to malaria because
they are still in the process of acquiring nat-
ural immunity [28-30]. In Cameroon, age
was a major risk factor for placental malaria,
with younger, first-time mothers more likely
to have placental malaria [1]. Similarly in
Zaire, mothers with malarious placentas
were younger (mean age 24 years old) than
mothers with non-malarious placentas
(mean age 29 years old) [14]. It was sug-
gested that development of pregnancy-asso-
ciated immunity, i.e., production of
antibodies that inhibit the adherence of pla-
cental parasites to chondroitin sulfate A
(CSA), may be very important in women
younger than 25 who have lower levels of
acquired immunity (through less frequency
of exposure to the bites of P. falciparum-in-
fected mosquitoes) than in older women
who may have obtained adequate immunity
following repeated exposures and thus are
less dependent on anti-cytoadherent antibod-
ies [1]. However, it is important to state that
in malarious areas, pregnancy-associated
and age-dependent immunity to placental
malaria may be influenced by host or envi-
ronmental factors.
PARITY AND HEALTH
The relationship between placental
malaria and parity is well established. Many
recent studies have found the prevalence to
be higher in primigravidae than multigravi-
dae, and in these studies, results are con-
trolled for age [1,31,32].These observations
are consistent with the findings of earlier
studies in malaria-endemic regions, where,
among several factors, parity independently
influenced the placental malaria prevalence
rate, with primigravidae having a two- to
four-fold increased risk of placental malaria
compared to multigravidae [33,34]. In the
Gambia, it was observed that the severest
form of placental parasitization occurred in
a higher proportion of the primigravidae
than in the multigravidae [31].
In theTanga region ofTanzania, placen-
tal malaria was associated with hypertension
in young first-time mothers with histologic
features of chronic disease but was not re-
lated to hypertension in older or multigravid
women. Similarly, placental malaria was as-
sociated with elevated levels of placentally
derived soluble vascular endothelial growth
factor receptor 1 (sVEGFR1†) in first-time
mothers but not in multigravid mothers with
age being controlled [35]. sVEGFR1 may
cause systemic endothelial dysfunction by
binding to and sequestering free serum vas-
cular endothelial growth factor (VEGF) and
placental growth factor [36,37], which is as-
sociated with higher risk adverse perinatal
outcome among primigravidae with as much
risk as up to 25 percent [36]. The exact rea-
son why primigravidae are more susceptible
to placental malaria and suffer from its con-
sequences more than multigravidae is yet to
be fully elucidated. However, a common ex-
planation is that pregnancy is associated
with a decrease in immunity, which is more
pronounced in primigravidae than in multi-
gravidae and may be associated with age
[38]. Immunological studies have shown
that this increase in susceptibility could be
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cytes to adhere to chondroitin sulfate A
(CSA) expressed by the syncytiotrophoblast
of the placenta [39,40]. Thus, the placenta
may select for the CSA-binding P. falci-
parum phenotype, putting primigravidae
with no previous exposure to this parasite
form at increased risk for developing placen-
tal malaria. The decreasing susceptibility to
pregnancy-associated malaria with increas-
ing parity is reflected in the acquisition of
antibodies specific to parasites’variant anti-
gens expressed on the surface of infected
erythrocytes [41].Another possible explana-
tion for this parity-related susceptibility is
given by the findings of Duffy and Fried
[42], who showed that multigravid mothers
develop malaria antibodies that block adhe-
sion of parasites to CSAreceptors in the pla-
centae in subsequent pregnancies. More
studies using both immunological and mo-
lecular biological tools are urgently needed
to properly elucidate this parity-related sus-
ceptibility to placental malaria. However,
since pregnant women in malarious areas
produce antibodies that specifically recog-
nize CSA-binding P. falciparum, this could
form a basis for the development of a vac-
cine to protect pregnant women against pla-
cental malaria.
PERIPHERAL MALARIA INFECTION
The relationship between maternal pe-
ripheral parasitemia and placental malaria
has been evaluated in some parts of sub-Sa-
haran Africa. There are no rigorous studies
on whether placental infection reflects the
existence of peripheral infection over a short
period preceding the delivery or whether it is
related to infection during pregnancy. Two
studies have shown some relation between
a late infection (i.e., infection acquired late
in pregnancy) and positivity of placental
smears or presence of pigment [43,44], but it
has been argued that a single measure can
hardly reflect the entire history of infection
during pregnancy. In one study, the occur-
rence of peripheral parasitemia at the begin-
ning and at the end of pregnancy was
significantly related to placental infection,
whereas peripheral parasitemia in the middle
of pregnancy was not [38]. This suggests
that a peripheral parasitemia at the begin-
ning of pregnancy may persist within the
placenta throughout gestation, with possibly
more severe consequences for the placenta
and the newborn, than an infection acquired
later in pregnancy. Other studies have shown
that peripheral infection confers a five-fold
increased risk for placental malaria, thus
confirming the importance of late maternal
infections [38]. Although maternal periph-
eral infection toward the end of pregnancy
(post seven months) predisposes the woman
to placental malaria, risk of placental infec-
tion is greater if peripheral infection occurs
at the beginning of pregnancy [45]. In
Malawi, placental infection was more fre-
quent in women who were infected at enroll-
ment in the study (i.e., during the first
trimester of pregnancy) than those who were
not infected at enrollment [46]. Early pe-
ripheral infection during pregnancy may be
a particularly important risk factor for pla-
cental infection, due to lower immune pro-
tection at the beginning of pregnancy.
Nevertheless, susceptibility may be corre-
lated to high exposure to malaria, and re-
peated episodes of parasitemia, as well as
the interplay between several other factors,
should form the basis for further investiga-
tions.
CONCLUSIONS: PUBLIC HEALTH
CONSIDERATIONS
Despite considerable improvement in
healthcaredeliveryservicesintheAfricancon-
tinent, the control of malaria in pregnant
African women, one of several child survival
strategies applied through antenatal care, con-
tinuestobeparticularlychallenging.Prevention
andcontrolrecommendationsfortypicalareas
of high P. falciparum transmission have pro-
moted the use of antimalarial chemoprophy-
laxis to prevent placental infection and its
associated adverse perinatal outcome. This
confirmspriorfindings[47].Otherrandomized
trialsshowaprotectiveeffectofprophylaxison
placental infection or peripheral parasitemia
[46,48,49].However,persistentlylowprogram
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tioneffectivenesshasforcedare-evaluationof
therelativeimportanceofmalariainpregnancy
[50].Theprophylacticmedicinesincludesulfa-
doxine pyremethamine, proguanil and
pyremethamine, while the curative ones in-
clude artesunate, chloroquine and amodi-
aquine. These drugs are relatively safe in
pregnancy and are widely used in malarious
areasof sub-SaharanAfrica[51].
In the face of the mounting evidence of
the relative failure of many traditional anti-
malarial drugs, particularly chloroquine, the
World Health Organization (WHO) has put
forward new guidelines for combating and
preventing malaria during pregnancy
[24,51]. The guidelines recommend that
women living in high transmission areas of
Africa receive intermittent preventive treat-
ment (IPT) with an effective antimalarial
agent such as sulfadoxine-pyrimethamine
(SP) at scheduled antenatal visits and that all
pregnantwomenintargetedareasshouldun-
dergo at least two sessions of IPT after first
fetal movements (i.e., between 20 and 35
weeks) [51]. Unfortunately, the implementa-
tion of the WHO guidelines has been bur-
dened by the notorious problems
complicating health service delivery in the
developing world, particularly in theAfrican
continent, namely, the logistical challenges
ofreachingremoteregions,resourcescarcity,
lack of infrastructure, inadequate treatment,
continuing poverty, and armed conflict.
It is well established that women in
Africauseprenatalcareextensivelywhenitis
available and accessible. This opportunity
must be used to implement evidence-based
actions with appropriate and realistic goals.
There is an urgent need to improve access of
rural women to antenatal clinic services in
sub-SaharanAfrica,eitherthroughincreasing
thenumberofruralhealthcentersorbyestab-
lishingfunctioningoutreachservices.Thedis-
tributionof insecticide-treated bed nets needs
to become implemented on a large scale.
Since pregnant women have increased
specific risks of complications from both
malaria and HIVinfection, the financial and
human resource constraints of health sys-
tems in countries most affected by malaria
and HIVand the shared determinants of vul-
nerability for both diseases indicate the need
for integration of preventive and curative
services for malaria and HIV. The health
systems that deliver these services must be
strengthened [22]. Reproductive health serv-
ices offer a critical opportunity for routine
provider-initiated HIV testing and counsel-
ing. They can provide follow-up care with
prevention of MTCT interventions accord-
ing to national policy for those who test pos-
itive, coupled with entry to antiretroviral
therapy programs for those sick and in need
of immediate therapy. These services need
to be strengthened to ensure the delivery of
the WHO-recommended antenatal care
schedule of four visits (focused antenatal
care), which includes a minimum package
of interventions for the prevention of both
malaria and HIV [52].
Studies in malarious regions have
demonstrated that substantial reductions in
maternal malaria, anemia, and low birth
weight have been achieved by intervention
programs,includingtheuseofpreventivein-
termittent treatment, chemoprophylaxis, and
the use of insecticide-treated nets. In fact,
studies suggest that between 25 percent and
90 percent of these adverse events might be
prevented by full implementation of existing
interventions [12]. Interventions therefore
should also exist for maternal anemia (e.g.,
good nutrition, iron and folate supplementa-
tion,andhookwormtreatment)andforreduc-
tion of mother-to-infant HIV transmission
(e.g.,short-coursezidovudineornevirapine),
and such can be provided through antenatal
care programs [22,53-56]. Better application
of these malaria, anemia, and HIV interven-
tions could markedly reduce the infant mor-
tality burden of these diseases.
Finally, collaboration between scien-
tists, policy makers and control programs
should be strengthened and community-
level research encouraged in order to guide
programs and monitor and evaluate markers
of success.
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